1. Report Overview
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches
2. Executive Summary
3. Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.2.4. Challenges
3.3. PEST-Analysis
3.4. Porter's Diamond Model for United States Anti-malarial Drugs Market
3.5. IGR-Growth Matrix Analysis
3.6. Value Chain Analysis of United States Anti-malarial Drugs Market
3.7. Competitive Landscape in United States Anti-malarial Drugs Market
4. The United States Anti-malarial Drugs Market by Drug Class
4.1. Quinine
4.2. Chloroquine
4.3. Proguanil
4.4. Mefloquine
4.5. Others
5. The United States Anti-malarial Drugs Market by Route of Administration
5.1. Oral
5.2. Injectable
6. The United States Anti-malarial Drugs Market by Distribution Channel
6.1. Hospital Pharmacy
6.2. Retail Pharmacy
6.3. E-commerce
6.4. Others
7. Company Profiles
7.1. Company 1
7.2. Company 2
7.3. Company 3
7.4. Company 4
7.5. Company 5
1. Report Overview
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches
2. Executive Summary
3. Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.2.4. Challenges
3.3. PEST-Analysis
3.4. Porter's Diamond Model for the United States Anti-malarial Drugs Market
3.5. IGR-Growth Matrix Analysis
3.6. Value Chain Analysis of the United States Anti-malarial Drugs Market
3.7. Competitive Landscape in the United States Anti-malarial Drugs Market
4. The United States Anti-malarial Drugs Market by Drug Class
4.1. Quinine
4.2. Chloroquine
4.3. Proguanil
4.4. Mefloquine
4.5. Others
5. The United States Anti-malarial Drugs Market by Route of Administration
5.1. Oral
5.2. Injectable
6. The United States Anti-malarial Drugs Market by Distribution Channel
6.1. Hospital Pharmacy
6.2. Retail Pharmacy
6.3. E-commerce
6.4. Others
7. Company Profiles
7.1. Company 1
7.2. Company 2
7.3. Company 3
7.4. Company 4
7.5. Company 5